Lipoprotein(a): The Hidden Genetic Heart Risk That 2026 Drug Trials May Finally Solve

Roughly one in five adults worldwide carries a genetic condition that roughly doubles their lifetime risk of heart attack, stroke, and calcific aortic valve disease. It is not measured on a standard cholesterol panel. It cannot be lowered meaningfully by diet, exercise, or statins. Most cardiologists do not routinely test for it. And until very recently, no drug could touch it.

Presented By Our Partners

That is beginning to change. Lipoprotein(a), or Lp(a), has moved from a research curiosity to the most urgent unmet need in preventive cardiology. In 2026, the field is on the cusp of its first definitive outcomes trial results for a class of drugs designed to lower Lp(a) directly, and the implications for cardiovascular longevity may rival the arrival of statins four decades ago.

What Lipoprotein(a) Actually Is

Lipoprotein(a) is a particle that looks superficially like LDL cholesterol, the so called "bad cholesterol" most people have heard of. It consists of an LDL like core wrapped in apolipoprotein B, plus a unique protein called apolipoprotein(a), or apo(a), attached by a disulfide bond. The apo(a) protein is structurally similar to plasminogen, the molecule the body uses to dissolve clots, which has led to one of the leading hypotheses about why Lp(a) is so atherogenic. It may simultaneously accelerate plaque formation and impair the body’s ability to clear blood clots. Lp(a) also carries oxidized phospholipids, pro inflammatory cargo that may drive both atherosclerosis and the calcification of the aortic valve.

Unlike LDL, Lp(a) levels are roughly 80 to 90 percent determined by a single gene, LPA, located on chromosome 6. Your Lp(a) concentration is essentially set at birth and remains relatively stable throughout life. Lifestyle has almost no effect. Statins, which dramatically lower LDL, do not meaningfully lower Lp(a). In fact, some studies suggest statins may modestly raise Lp(a) levels, although the clinical relevance of that increase remains debated. This genetic immovability is what makes Lp(a) so frustrating, and what makes the prospect of a targeted drug so consequential.

The Evidence That Lp(a) Causes Heart Disease

For decades, the argument that Lp(a) caused cardiovascular disease rested on observational studies. Epidemiologists noted that people with higher Lp(a) levels had more heart attacks, more strokes, and more calcific aortic valve disease, but association is not causation. The field needed a way to prove that Lp(a) itself, rather than some confounder, was driving the risk.

That evidence came from Mendelian randomization, a genetic epidemiology technique that uses inherited genetic variants as proxies for lifelong exposure to a biomarker. Because genetic variants are randomly assigned at conception, they are less susceptible to confounding than traditional observational data. In 2009, Borge Nordestgaard and colleagues at the University of Copenhagen published a landmark Mendelian randomization analysis in JAMA showing that people born with LPA gene variants that elevate Lp(a) had a substantially higher lifetime risk of myocardial infarction, independent of LDL, blood pressure, diabetes, and smoking.

That finding was replicated and extended by multiple groups. A 2018 paper by Pia Kamstrup and colleagues in the European Heart Journal analyzed data from the Copenhagen General Population Study, following more than 60,000 individuals, and confirmed a dose response relationship between Lp(a) level and cardiovascular mortality. In 2019, Sotirios Tsimikas of the University of California San Diego, widely regarded as the leading clinician scientist working on Lp(a), published a comprehensive review in the Journal of the American College of Cardiology arguing that the totality of genetic, epidemiological, and mechanistic evidence met the causal criteria articulated by Austin Bradford Hill more than half a century ago.

By 2022, when the European Atherosclerosis Society issued its updated consensus statement on Lp(a), the group led by Florian Kronenberg of the Medical University of Innsbruck concluded that Lp(a) should be considered a causal risk factor for atherosclerotic cardiovascular disease and for calcific aortic valve stenosis. The statement recommended that every adult should have Lp(a) measured at least once in a lifetime, a recommendation echoed by the Canadian Cardiovascular Society and, more cautiously, by the American College of Cardiology and American Heart Association.

How Common Is Elevated Lp(a)?

Estimates vary by ancestry, measurement method, and threshold, but the scale is striking. Roughly 20 to 25 percent of the global population, approximately 1.4 billion people, have Lp(a) levels above 50 milligrams per deciliter, the threshold most guidelines use to flag elevated cardiovascular risk. Prevalence is higher in people of African ancestry, where median Lp(a) concentrations are roughly two to three times higher than in European populations, and lower in East Asian populations. The distribution within any given population is highly skewed. Most people have modest Lp(a) levels, but a substantial minority carry concentrations that translate into double or even triple the baseline risk of coronary disease.

In the Copenhagen Heart Study, individuals with Lp(a) above the 95th percentile had a two to three fold higher risk of myocardial infarction compared to those at the median, even after adjusting for every other known risk factor. Put differently, a lean, non smoking, marathon running 45 year old with an LDL of 70 and an elevated Lp(a) may carry the cardiovascular risk profile of a sedentary peer with an LDL of 160. That is what makes Lp(a) so pernicious. It is invisible to the standard risk models that dominate primary care.

Why Lp(a) Has Been Largely Ignored

If the evidence is so clear and the prevalence so high, why has Lp(a) testing remained uncommon? Three reasons dominate.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

First, until recently, there was no treatment. Clinicians are understandably reluctant to order a test that cannot be acted on. Lifestyle modification, the default response to most cardiovascular risk factors, does essentially nothing for Lp(a). Intensive statin therapy, which reduces the overall atherosclerotic burden, still leaves the Lp(a) mediated residual risk largely in place. The only interventions that meaningfully lower Lp(a) before the current pipeline were lipoprotein apheresis, a blood filtering procedure reserved for the highest risk patients in specialized centers, and PCSK9 inhibitors, which reduce Lp(a) modestly as a side effect of their LDL lowering action.

Second, measurement has been inconsistent. Historically, Lp(a) has been reported in milligrams per deciliter, a mass unit that varies based on the molecular weight of individual apo(a) isoforms. Because apo(a) size differs dramatically between individuals, mass based assays can misclassify risk. The newer nanomole per liter assays, which count particles rather than measuring mass, give more consistent results. The shift has been slow and uneven across laboratories, and many physicians remain unsure how to interpret the two different unit systems.

Third, there has been a persistent perception that Lp(a) was a scientific curiosity rather than a clinical actionable. Risk calculators like the pooled cohort equations, which form the backbone of cardiovascular risk assessment in the United States, do not incorporate Lp(a). Medical schools have historically treated it as a footnote. That perception is now collapsing under the weight of new data and new therapies.

The Drug Pipeline Closing In on Lp(a)

The therapeutic revolution in Lp(a) has been driven by RNA targeting drugs, specifically antisense oligonucleotides and small interfering RNAs, that silence the LPA gene directly in liver cells, where apo(a) is produced. These platforms represent one of the clearest modern demonstrations of how genetic target validation can feed directly into drug design.

Pelacarsen, developed by Ionis Pharmaceuticals and licensed to Novartis, is the most clinically advanced. It is an antisense oligonucleotide conjugated to a GalNAc sugar that targets liver hepatocytes selectively. Phase 2 data published by Tsimikas and colleagues in The New England Journal of Medicine in 2020 showed pelacarsen reduced Lp(a) by roughly 80 percent at the highest dose. The Lp(a)HORIZON trial, the first cardiovascular outcomes trial specifically testing whether lowering Lp(a) reduces heart attacks and strokes, has enrolled more than 8,000 patients with established cardiovascular disease and elevated Lp(a). Topline results are expected in 2026, making this year one of the most consequential in modern preventive cardiology.

Olpasiran, developed by Arrowhead Pharmaceuticals and licensed to Amgen, is a small interfering RNA that also targets LPA messenger RNA in the liver. Phase 2 data from the OCEAN(a) DOSE trial, published by Michelle O’Donoghue of the Brigham and Women’s Hospital TIMI Study Group in The New England Journal of Medicine in 2022, demonstrated Lp(a) reductions of more than 95 percent with quarterly or semi annual subcutaneous dosing. Olpasiran is now in the OCEAN(a) Outcomes trial, a large Phase 3 study with readout anticipated later in the decade.

Lepodisiran, developed by Eli Lilly, is another GalNAc conjugated siRNA targeting apo(a). Its Phase 2 results, published in JAMA in 2024 by Steven Nissen of the Cleveland Clinic, showed single injections producing Lp(a) reductions exceeding 90 percent that persisted for nearly a year, raising the prospect of once yearly dosing. A cardiovascular outcomes trial, ACCLAIM Lp(a), is enrolling patients.

Muvalaplin, also from Eli Lilly, represents a different approach. It is an oral small molecule that blocks the assembly of the Lp(a) particle by preventing apo(a) from binding to apolipoprotein B100. Phase 1 data published in JAMA in 2023 and Phase 2 data in 2024 showed Lp(a) reductions of roughly 65 to 85 percent with a daily pill, potentially offering a more scalable option than injectable therapies for lower risk populations.

If one or more of these drugs demonstrates a meaningful reduction in cardiovascular events, the implications would be profound. Lp(a) mediated risk is estimated to account for 10 to 30 percent of premature coronary disease in the populations most affected. Closing that gap could translate to a substantial reduction in first and recurrent heart attacks, strokes, and aortic valve replacement surgeries over the coming decades. It would also set a precedent for targeted genetic lipid therapies that may extend beyond Lp(a) itself.

What the Guidelines Say Now

The 2022 European Atherosclerosis Society consensus, led by Kronenberg, recommends one time Lp(a) testing for every adult and risk reclassification based on the result. People with Lp(a) above 50 milligrams per deciliter, or roughly 125 nanomoles per liter, are considered to have elevated cardiovascular risk that warrants more aggressive management of modifiable factors. That typically means lower LDL targets, stricter blood pressure control, smoking cessation, weight management, and, for those with very high Lp(a) plus other risk factors, consideration of PCSK9 inhibitors, which modestly lower Lp(a) in addition to LDL.

The American Heart Association and American College of Cardiology have been more cautious, recommending Lp(a) testing primarily for patients with a personal or family history of premature cardiovascular disease, unexplained coronary events, or aortic stenosis. That conservative posture may shift quickly if Lp(a)HORIZON reads out positive. A favorable trial would likely trigger rapid guideline updates, reimbursement changes, and a restructuring of how cardiovascular risk is assessed globally.

Lp(a) and the Longevity Conversation

For the longevity field, Lp(a) offers something unusual. It is a single, measurable, highly causal, lifelong risk factor that has been flying under the radar. Most longevity interventions target aging biology broadly, with uncertain timelines to benefit and limited randomized evidence. Lp(a) is different. The biology is well understood. The genetic causality is established beyond reasonable doubt. And the therapies under development are not general purpose lifestyle tools but targeted molecular drugs with the potential to cut cardiovascular risk in half or more for the people who carry elevated levels.

If you care about cardiovascular healthspan, which is to say how many years you will live free of heart attack, stroke, and valvular disease, knowing your Lp(a) is arguably the single highest value test you can do. It is cheap. It is available. You need to do it only once. And the result may change the rest of your medical decisions for the next fifty years.

What This Means For You

Get your Lp(a) measured. The test costs between twenty and one hundred dollars and is covered by many insurers when ordered by a physician. You need to do it only once in your life, because your level is essentially fixed at birth. Request the nanomole per liter assay if your laboratory offers it, as mass based assays are less reliable.

If your Lp(a) is below 30 milligrams per deciliter, roughly 75 nanomoles per liter, your Lp(a) is not a clinical concern. If it falls between 30 and 50, it is a yellow flag that should sharpen your attention to every other modifiable risk factor. Above 50 is elevated. Above 180 milligrams per deciliter, or roughly 430 nanomoles per liter, it is considered very high and warrants referral to a lipid specialist or preventive cardiologist.

Regardless of the result, you cannot fix Lp(a) today with lifestyle. But if your level is elevated, you can and should optimize every other modifiable cardiovascular risk factor more aggressively than you otherwise would. That means a lower LDL target, often below 70 milligrams per deciliter for those with elevated Lp(a) and other risk factors, tight blood pressure control, no smoking, regular aerobic and resistance exercise, and, if overall risk is high, a thoughtful conversation with your physician about statins and possibly PCSK9 inhibitors.

If you have an elevated level and a family history of early heart disease, ask your physician about enrollment in ongoing Lp(a) outcomes trials. Clinical trial participation may be the fastest path to access a therapy that can directly lower your Lp(a) years before any of these drugs reach the broader market.

Finally, ask your first degree relatives to check their Lp(a) as well. Because Lp(a) is inherited, your level is predictive of your siblings’ and your children’s levels. A single generation of testing can identify everyone in the family who needs more intensive cardiovascular prevention, and it can prompt earlier screening of children and grandchildren in families with a strong history of premature coronary disease.

The Lp(a) story is one of the clearest examples in modern medicine of a discovery that was ahead of its therapy. For sixty years, the science has been building. In 2026, the treatment finally has a chance to catch up. Whether you are 30 or 70, whether your cholesterol is perfect or problematic, this is the year to add Lp(a) to your health literacy and to your next conversation with your doctor.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.